English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, January 3, 2024
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組
Thursday, March 30, 2023
冠科美博(Apollomics Inc.)宣佈完成和SPAC Maxpro合併,並在納斯達克上市
冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
Tuesday, July 26, 2022
冠科美博 (Apollomics Inc.) 扩充其领导团队,任命 Jane Wang 博士担任首席科学官一职
冠科美博 (Apollomics Inc.) 擴充其領導團隊,任命 Jane Wang 博士擔任首席科學官一職
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
Wednesday, January 12, 2022
冠科美博 (Apollomics Inc.) 将于 2022 年 1 月 26-27 日(周三、周四)举办线上投资者活动
冠科美博 (Apollomics Inc.) 將於 2022 年 1 月 26-27 日(週三、週四)舉辦線上投資者活動

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575